Arthex Biotech Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$87M
- Investors
-
17
Arthex Biotech General Information
Description
Developer of oligonucleotide therapeutics designed for the treatment of diseases with unmet needs. The company develops drugs and therapies that are designed to treat a variety of disorders, enabling medical professionals to get access to therapy that helps treat patients suffering from genetic diseases, rare diseases, and diseases with high medical needs.
Contact Information
Website
www.arthexbiotech.comCorporate Office
- Calle Eduardo Primo Yúfera 3
- 46012 Valencia
- Spain
Corporate Office
- Calle Eduardo Primo Yúfera 3
- 46012 Valencia
- Spain
Arthex Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B) | 17-Sep-2025 | $87M | Completed | Clinical Trials - General | ||
| 7. Grant | 25-Oct-2022 | Completed | Clinical Trials - General | |||
| 6. Accelerator/Incubator | 01-Jun-2021 | Completed | Clinical Trials - General | |||
| 5. Grant | 28-Nov-2020 | Completed | Clinical Trials - General | |||
| 4. Seed Round | 23-Jul-2020 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 02-Jun-2020 | Completed | Clinical Trials - General | |||
| 2. Angel (individual) | 01-Dec-2019 | $3.58M | $3.58M | Completed | Stealth | |
| 1. University Spin-Out | 27-Sep-2019 | Completed | Stealth |
Arthex Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Arthex Biotech Comparisons
Industry
Financing
Details
Arthex Biotech Competitors (6)
One of Arthex Biotech’s 6 competitors is Vertex Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| AMO Pharma | Formerly VC-backed | London, United Kingdom | ||||
| PepGen | Formerly VC-backed | Boston, MA | ||||
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA |
Arthex Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arthex Biotech Patents
Arthex Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026139584-A1 | Synthesis of lipid-conjugated oligonucleotides | Pending | 24-Dec-2024 | ||
| WO-2026115091-A1 | Oligonucleotides conjugated to oleic acid and uses thereof | Pending | 28-Nov-2024 | ||
| AU-2024390166-A1 | Oligonucleotides conjugated to oleic acid and uses thereof | Pending | 28-Nov-2023 | ||
| EP-4815992-A1 | Oligonucleotides conjugated to oleic acid and uses thereof | Pending | 28-Nov-2023 | ||
| WO-2025114442-A1 | Oligonucleotides conjugated to oleic acid and uses thereof | Inactive | 28-Nov-2023 | A61K47/542 |
Arthex Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Arthex Biotech Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Caixa Capital Risc | Corporate Venture Capital | Minority | ||
| Columbus Venture Partners | Venture Capital | Minority | ||
| Criteria Capital Risc | PE/Buyout | Minority | ||
| Hadean Ventures | Venture Capital | Minority |
Arthex Biotech FAQs
-
When was Arthex Biotech founded?
Arthex Biotech was founded in 2019.
-
Where is Arthex Biotech headquartered?
Arthex Biotech is headquartered in Valencia, Spain.
-
What is the size of Arthex Biotech?
Arthex Biotech has 25 total employees.
-
What industry is Arthex Biotech in?
Arthex Biotech’s primary industry is Drug Discovery.
-
Is Arthex Biotech a private or public company?
Arthex Biotech is a Private company.
-
What is Arthex Biotech’s current revenue?
The current revenue for Arthex Biotech is .
-
How much funding has Arthex Biotech raised over time?
Arthex Biotech has raised $95.1M.
-
Who are Arthex Biotech’s investors?
Bpifrance, Caixa Capital Risc, Columbus Venture Partners, Criteria Capital Risc, and Hadean Ventures are 5 of 17 investors who have invested in Arthex Biotech.
-
Who are Arthex Biotech’s competitors?
Vertex Pharmaceuticals, AMO Pharma, PepGen, Dyne Therapeutics, and Arrowhead Pharmaceuticals are some of the 6 competitors of Arthex Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
